Form 4: Zymeworks Director Cherry Receives Equity Grants

Zymeworks Inc. Director Brian N. Cherry was granted 23,000 stock options and 15,400 restricted stock units.

Summary

• Director Brian N. Cherry of Zymeworks Inc. was granted 23,000 stock options and 15,400 restricted stock units (RSUs) on January 12, 2026.
• The stock options have an exercise price of $23.16 and will vest in 36 equal monthly installments, commencing one month after the grant date.
• The stock options are set to expire on January 11, 2036.
• Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting.
• The RSUs will vest in three equal annual installments, beginning on the first anniversary of the grant date.

Sentiment

Score: 5

Explanation: This is a routine Form 4 filing detailing director compensation, which is neutral in terms of immediate positive or negative sentiment regarding company performance or outlook.

Positives

• The grant of stock options and restricted stock units aligns the director's interests with long-term shareholder value through equity ownership.
• The multi-year vesting schedules for both the stock options (36 months) and RSUs (3 years) encourage sustained commitment and performance from the director.

Negatives

• No specific negative financial or operational information is disclosed in this routine insider transaction report.

Future Outlook

This filing details future vesting schedules for equity grants, indicating a long-term incentive structure for the director, aligning their interests with the company's future performance.

Industry Context

The granting of stock options and restricted stock units to directors is a common practice in the biotechnology and pharmaceutical industry, used to attract, retain, and incentivize key leadership by aligning their financial interests with the company's long-term performance and shareholder value.

Comparison to Industry Standards

• Equity compensation for directors, including stock options and restricted stock units with multi-year vesting schedules, is a standard practice across publicly traded companies, particularly in the high-growth biotechnology sector.
• The specific mix and volume of equity grants are typically benchmarked against peer companies of similar market capitalization and stage of development to ensure competitive compensation packages.

Stakeholder Impact

• Shareholders: The equity grants align the director's interests with shareholders, potentially fostering long-term value creation.
• Employees: This filing is specific to a director's compensation and does not directly impact general employees.

Next Steps

• Vesting of 23,000 stock options in 36 equal monthly installments starting one month after January 12, 2026.
• Vesting of 15,400 restricted stock units in three equal annual installments beginning on the first anniversary of January 12, 2026.

Key Dates

Keywords

Zymeworks, ZYME, Form 4, insider transaction, director compensation, stock options, restricted stock units, equity grant, corporate governance